Skip to main content

Table 2 Baseline characteristics and scheduled hemoglobin evaluation visit per study and site

From: Delayed anemia assessment in patients treated with oral artemisinin derivatives for uncomplicated malaria: a pooled analysis of clinical trials data from Mali

Study*

Site

N

Haemogobin evaluation days

Age median [min, max]

P. f.

Anaemia prev.

[13] (2010–11)

Bougoula- Hameau

100

0, 3, 14, 28

6 [1,11]

28,027

48%

UO (2009)

Kolle

77

0, 14, 28

6 [1,18]

44,492

55%

Faladje

88

6 [1,14]

47,942

26%

Bandiagara

100

7 [1, 61]

32,703

28%

Pongonon

72

5 [1, 34]

18,841

43%

[14] (2007–08)

Bougoula- Hameau

130

0, 3, 7, 28

6 [2,10]

32,430

31%

[15] (2007)

Bougoula- Hameau

198

0, 3, 7, 28

11 [6, 52]

22,115

11%

[16] (2006)

Bancoumana

203

0, 7, 14, 28

5 [0.9, 24]

22,183

50%

[17] (2005–07)

Bougoula- Hameau

771

0, 7, 14, 28

4 [0.5, 69]

20,463

50%

[18] (2005)

Faladje

400

0, 14, 28

36 [6, 60]

23,705

48%

[19] (2004–05)

Kambila

470

0, 14, 28

6 [1,70]

18,258

13%

[20] (2003–04)

Sotuba

606

0, 28

11 [0.6, 63]

13,592

14%

[21] (2002–04)

Bougoula- Hameau

752

0, 3, 7, 14, 28

3 [0.6, 56]

15463

44%

UO (2002–04)

Kolle

655

0, 7, 14

7 [0.5, 64]

12200

25%

Bandiagara

293

6 [0.7, 30]

12686

29%

UO (2002–03)

Bougoula- Hameau

619

0, 14, 28

3 [0.5, 65]

14897

42%

[22] (2002–03)

Kolle

456

0, 7, 14, 28

3 [0.3, 6]

19778

51%

Total

 

5,990

 

5 [0.3, 70]

17,789

36%

  1. Note: P. f., Plasmodium falciparum geometric mean; Anaemia prev. (dichotomous variable), anaemia prevalence. Anaemia was defined as haemoglobin value <10.0 g/dL; Numbers in first column represent publication references as cited in the text.
  2. *The studies are citied in descending order from conduct year ranging from 2011 to 2002. The number given is their publication reference as applicable.
  3. UO, unpublished observations.